AI-powered search

COVID-19 Mainly Mild, Moderate in Eczema Patients Receiving Tralokinumab

76 of 77 patients with COVID-19 were unvaccinated; no new safety signals reported after COVID-19 vaccination

By Dermsquared Editorial Team | October 12, 2022

For patients with atopic dermatitis (AD) enrolled in the ECZTEND trial and receiving tralokinumab, COVID-19 infections were mainly mild or moderate and almost all occurred in unvaccinated patients, according to a research letter published online Oct. 12 in JAMA Dermatology .

Andrew Blauvelt, M.D., from Oregon Medical Research Center in Portland, and colleagues conducted a case series in a subset of adults enrolled in the ongoing ECZTEND trial who received 300 mg subcutaneous tralokinumab every two weeks plus optional topical corticosteroids after a 600-mg loading dose and reported COVID-19 during routine clinic visits. Of 1,442 patients enrolled in the ECZTEND trial, 77 had confirmed COVID-19 (76 were unvaccinated and one was partially vaccinated).

The researchers found that COVID-19 severity was mainly mild or moderate (68 and 30 percent, respectively); two patients (3 percent) had severe symptoms, both of whom had multiple risk factors for severe COVID-19 and both of whom recovered after hospitalization. Neither case was reported as linked to treatment with tralokinumab. Two cases of COVID-19 were reported as possibly associated with tralokinumab; both occurred in patients younger than 30 years. No deaths were reported from COVID-19. After COVID-19, all patients continued tralokinumab therapy; treatment was not interrupted in 60 patients (78 percent). As of April 30, 2021, 16 percent of participants in the trial had received one or more COVID-19 vaccine doses; no patients reported adverse events resulting in permanent discontinuation of tralokinumab after vaccination.

"No new safety signals or evidence for reduced effectiveness of severe acute respiratory syndrome coronavirus 2 vaccines administered during tralokinumab treatment were reported," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Leo Pharma, the manufacturer of tralokinumab.

Abstract/Full Text (subscription or payment may be required)


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved